Lung Cancer

China’s NMPA approved ivonescimab for the first-line treatment of PD-L1–positive advanced non–small cell lung cancer.

Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved with new combination therapies like osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) challenging osimertinib monotherapy as the standard of care.

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Panelists discuss how comprehensive biomarker testing in early-stage disease settings provides crucial molecular insights that guide surgical planning and inform critical decisions about neoadjuvant, perioperative, and adjuvant treatment strategies.

Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.

Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

Panelists discuss how medical professionals frequently encounter tissue adequacy challenges in comprehensive genomic profiling for early-stage non–small cell lung cancer (NSCLC), employing strategies such as optimized biopsy techniques, efficient tissue triage protocols, and complementary liquid biopsies to ensure sufficient material for complete molecular analysis.

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

Panelists discuss how medical professionals currently approach molecular testing in early-stage non–small cell lung cancer (NSCLC) through comprehensive biomarker analysis, including targeted next-generation sequencing (NGS), to identify actionable mutations that guide adjuvant therapy decisions and improve patient outcomes.

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Fawzi F Abu Rous, MD, discusses the need for reliable predictive biomarkers for therapeutic development in squamous cell carcinoma of the lung.

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.

Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.